Nama's AI scorecard currently rates Definium Therapeutics Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does DFTX report earnings?

Definium Therapeutics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.56.

What is the DFTX price target?

The median analyst price target from 18 analysts is $71.00, with a range of $55.00 – $91.00.

Is DFTX Shariah compliant?

Nama's AAOIFI-style screen reads Definium Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Definium Therapeutics (DFTX)

Healthcare · Biotechnology · NASDAQ

Definium Therapeutics (DFTX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $4.47B and a free-cash-flow yield of -4.4%. Nama's AI scorecard rates it Sell, 3.5 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.5/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +209.4% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-33.1%

How far the last close sits under the highest price of the past five years.

Market cap	$4.47B
Trailing P/E	—
Price / book	4.9
Price / sales	—
FCF yield	-4.4%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

DFTX earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.56). Beat the EPS estimate in 0 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 6, 2026	-$1.44	-$0.55	-161.8%	$0
Q1 2026	May 7, 2026	-$0.71	-$0.49	-44.9%	$0
Q4 2025	Feb 26, 2026	-$0.50	-$0.49	-2.0%	$0
Q3 2025	Nov 6, 2025	-$0.78	-$0.50	-56.0%	$0

DFTX analyst price target

Median target $71.00 from 18 analysts, ranging $55.00 – $91.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live DFTX data on Nama Insights →

DFTX FAQ

Is DFTX a buy?: Nama's AI scorecard currently rates Definium Therapeutics Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does DFTX report earnings?: Definium Therapeutics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.56.
What is the DFTX price target?: The median analyst price target from 18 analysts is $71.00, with a range of $55.00 – $91.00.
Is DFTX Shariah compliant?: Nama's AAOIFI-style screen reads Definium Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.